Table 2.
Outcomes of the mebendazole treatment group and the nonmebendazole treatment group for both inpatients and outpatients.
| Inpatients | Outpatients | |||||
|---|---|---|---|---|---|---|
| Control | Treatment | P value | Control | Treatment | P value | |
| N | 89 | 68 | 91 | 94 | ||
| Death | 8 (9.0) | 3 (4.4) | 0.35 | 0 (0) | 0 (0) | 1 |
| Ventilation | 7 (7.9) | 2 (2.9) | 0.30 | — | — | — |
| Hospital LOS | 10 (9, 12) | 7 (6, 9) | 6.0 × 10−8 | — | — | — |
| Need for hospitalization | — | — | — | 6 (6.6) | 3 (3.2) | 0.33 |
| Time to symptom resolution | — | — | — | 7 (6, 8) | 4 (3, 4) | 6.6 × 10−42 |
Continuous variables are presented as medians (interquartile range) and discrete variables are presented as counts (percentage). Continuous variables were compared by fitting multiple linear regression models, including the demographic and clinical covariates backward selected by the Akaike information criterion; discrete variables were compared using Fisher's exact test.